Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has continued to expand coverage for Ryoncil® (remestemcel-L), the ...

This video explores how plants became a source of healing and resistance for enslaved communities, inspired by our exhibition 'Hard Graft'.